kidney disease

Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
MedCity News
Mon, 07/25/22 - 10:33 am
HIF-PHI
kidney disease
FDA
vadadustat
Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus
Fierce Biotech
Tue, 07/19/22 - 10:21 am
Sanofi
kidney disease
Regulus
lademirsen
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Endpoints
Mon, 07/11/22 - 06:23 pm
Ionis Pharmaceuticals
Roche
IONIS-FB-LRx
clinical trials
immunoglobin A nephropathy
kidney disease
Medtronic to Spin Renal Business into New Company
Medical Devices and Diagnostics Industry
Thu, 05/26/22 - 10:42 pm
Medtech
kidney disease
Medtronic
spinoffs
DaVita
ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients
Fierce Pharma
Mon, 04/4/22 - 11:20 pm
Bayer
ACC
kidney disease
Kerendia
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
Yahoo/Businesswire
Tue, 03/22/22 - 09:59 am
Vertex Pharmaceuticals
kidney disease
VX-147
clinical trials
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
MedCity News
Mon, 02/28/22 - 09:15 am
Reata Pharmaceuticals
Bardoxolone
Alport syndrome
kidney disease
FDA
FDA knocks back Mallinckrodt’s kidney drug terlipressin
Pharmaforum
Wed, 02/23/22 - 10:26 am
Mallinckrodt
hepatorenal syndrome
kidney disease
terlipressin
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy
Fierce Biotech
Tue, 01/18/22 - 11:58 pm
ProKidney
SPACs
cell therapy
clinical trials
kidney disease
Vertex, needing research spark, finds promising results in small study of kidney disease drug
BioPharma Dive
Wed, 12/1/21 - 10:24 am
Vertex Pharmaceuticals
kidney disease
clinical trials
focal segmental glomerulosclerosis
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Pharmaforum
Fri, 11/5/21 - 09:54 am
Novartis
iptacopan
C3G
kidney disease
Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere
BioSpace
Sat, 09/18/21 - 08:23 pm
Vifor Pharma
Travere Therapeutics
kidney disease
Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug
Endpoints
Wed, 09/15/21 - 10:09 pm
Calliditas
FDA
Nefecon
kidney disease
Shanghai biotech tackling kidney disease gets another round of cash
Endpoints
Tue, 09/14/21 - 10:54 am
Alebund Pharmaceuticals
funding
kidney disease
ESC 2021: Bayer's Kerendia touts outcomes data as it looks to complement J&J, AZ drugs
Fierce Pharma
Sat, 08/28/21 - 09:02 pm
Bayer
ESC
finerenone
Kerendia
FDA
clinical trials
kidney disease
Bayer's Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patients
Fierce Pharma
Fri, 07/9/21 - 11:58 pm
Bayer
finerenone
Kerendia
kidney disease
heart disease
diabetes
type 2 diabetes
Farxiga
Sanofi's venglustat fails another trial, ending pursuit of kidney disease
Fierce Biotech
Tue, 06/1/21 - 11:02 am
Sanofi
venglustat
autosomal dominant polycystic kidney disease
kidney disease
clinical trials
FDA sets back Travere's plans for kidney disease drug approval
Fierce Biotech
Wed, 05/26/21 - 10:50 am
Travere Therapeutics
kidney disease
clinical trials
FDA
Retrophin
Martin Shkreli
FDA sets September review date for Calliditas’ rare kidney disease drug
Pharmaforum
Thu, 04/29/21 - 10:26 am
Calliditas
Nefecon
primary IgA nephropathy
kidney disease
FDA
Otsuka 'Big Kidney' campaign targets HCPs in bid to shift diagnostic standards
Fierce Pharma
Mon, 03/1/21 - 11:06 am
kidney disease
Otsuka
physicians
autosomal dominant polycystic kidney disease
pharma marketing

Pages